Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes

P. Hari, MV. Mateos, R. Abonour, S. Knop, W. Bensinger, H. Ludwig, K. Song, R. Hajek, P. Moreau, DS. Siegel, S. Feng, M. Obreja, SK. Aggarwal, K. Iskander, H. Goldschmidt,

. 2017 ; 31 (12) : 2630-2641. [pub] 20170425

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18016646
E-zdroje Online Plný text

NLK ProQuest Central od 1997-02-01 do Před 1 rokem
Open Access Digital Library od 1997-01-01
Nursing & Allied Health Database (ProQuest) od 1997-02-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1997-02-01 do Před 1 rokem
Public Health Database (ProQuest) od 1997-02-01 do 2017-12-31

Odkazy

PubMed 28439109
DOI 10.1038/leu.2017.122
Knihovny.cz E-zdroje

Autologous stem cell transplantation (ASCT) is a standard treatment for eligible multiple myeloma (MM) patients, but many patients will relapse after ASCT and require subsequent therapy. The proteasome inhibitor carfilzomib is approved for relapsed or refractory MM (RRMM). In phase 3 trials, carfilzomib-based regimens (ASPIRE, carfilzomib-lenalidomide-dexamethasone; ENDEAVOR, carfilzomib-dexamethasone) demonstrated superior progression-free survival (PFS) compared with standard therapies for RRMM (ASPIRE: lenalidomide-dexamethasone; ENDEAVOR, bortezomib-dexamethasone). This subgroup analysis of ASPIRE and ENDEAVOR evaluated outcomes according to prior ASCT status. In total, 446 patients in ASPIRE and 538 in ENDEAVOR had prior ASCT. Median PFS was longer for carfilzomib-based regimens vs non-carfilzomib-based regimens for patients with prior ASCT (ASPIRE: 26.3 vs 17.8 months (hazard ratio (HR)=0.68); ENDEAVOR: not estimable vs 10.2 months (HR=0.61)), those with one prior line of therapy that included ASCT (ASPIRE: 29.7 vs 17.8 months (HR=0.70); ENDEAVOR: not estimable vs 11.2 months (HR=0.46)), and those without prior ASCT (ASPIRE: 26.4 vs 16.6 months (HR=0.76); ENDEAVOR: 17.7 vs 8.5 months (HR=0.43)). Overall response rates also favored the carfilzomib-based regimens. No new safety signals were detected. This analysis suggests that carfilzomib-based treatment may lead to improvement in PFS and response rates regardless of prior transplant status. Further evaluation is warranted.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18016646
003      
CZ-PrNML
005      
20180515103620.0
007      
ta
008      
180515s2017 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/leu.2017.122 $2 doi
035    __
$a (PubMed)28439109
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Hari, P $u Medical College of Wisconsin, Milwaukee, WI, USA.
245    10
$a Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes / $c P. Hari, MV. Mateos, R. Abonour, S. Knop, W. Bensinger, H. Ludwig, K. Song, R. Hajek, P. Moreau, DS. Siegel, S. Feng, M. Obreja, SK. Aggarwal, K. Iskander, H. Goldschmidt,
520    9_
$a Autologous stem cell transplantation (ASCT) is a standard treatment for eligible multiple myeloma (MM) patients, but many patients will relapse after ASCT and require subsequent therapy. The proteasome inhibitor carfilzomib is approved for relapsed or refractory MM (RRMM). In phase 3 trials, carfilzomib-based regimens (ASPIRE, carfilzomib-lenalidomide-dexamethasone; ENDEAVOR, carfilzomib-dexamethasone) demonstrated superior progression-free survival (PFS) compared with standard therapies for RRMM (ASPIRE: lenalidomide-dexamethasone; ENDEAVOR, bortezomib-dexamethasone). This subgroup analysis of ASPIRE and ENDEAVOR evaluated outcomes according to prior ASCT status. In total, 446 patients in ASPIRE and 538 in ENDEAVOR had prior ASCT. Median PFS was longer for carfilzomib-based regimens vs non-carfilzomib-based regimens for patients with prior ASCT (ASPIRE: 26.3 vs 17.8 months (hazard ratio (HR)=0.68); ENDEAVOR: not estimable vs 10.2 months (HR=0.61)), those with one prior line of therapy that included ASCT (ASPIRE: 29.7 vs 17.8 months (HR=0.70); ENDEAVOR: not estimable vs 11.2 months (HR=0.46)), and those without prior ASCT (ASPIRE: 26.4 vs 16.6 months (HR=0.76); ENDEAVOR: 17.7 vs 8.5 months (HR=0.43)). Overall response rates also favored the carfilzomib-based regimens. No new safety signals were detected. This analysis suggests that carfilzomib-based treatment may lead to improvement in PFS and response rates regardless of prior transplant status. Further evaluation is warranted.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a transplantace hematopoetických kmenových buněk $7 D018380
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mnohočetný myelom $x farmakoterapie $x mortalita $x patologie $x terapie $7 D009101
650    _2
$a oligopeptidy $x aplikace a dávkování $7 D009842
650    _2
$a pooperační péče $7 D011182
650    _2
$a recidiva $7 D012008
650    _2
$a opakovaná terapie $7 D019233
650    _2
$a autologní transplantace $7 D014182
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Mateos, M-V $u Hematology, Hospital Clinico Universitario de Salamanca-IBSAL, Salamanca, Spain.
700    1_
$a Abonour, R $u Indiana University Simon Cancer Center, Indianapolis, IN, USA.
700    1_
$a Knop, S $u Medizinische Klinik der Universitat Wurzburg, Wurzburg, Germany.
700    1_
$a Bensinger, W $u Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
700    1_
$a Ludwig, H $u Leukemia/Bone Marrow Transplant Program of British Columbia, Vancouver, British Columbia, Canada.
700    1_
$a Song, K $u University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
700    1_
$a Hajek, R $u University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
700    1_
$a Moreau, P $u Department of Hematology, University of Nantes, Nantes, France.
700    1_
$a Siegel, D S $u John Theurer Cancer Center at Hackensack University, Hackensack, NJ, USA.
700    1_
$a Feng, S $u Amgen Inc., Thousand Oaks, CA, USA.
700    1_
$a Obreja, M $u Amgen Inc., Thousand Oaks, CA, USA.
700    1_
$a Aggarwal, S K $u Amgen Inc., Thousand Oaks, CA, USA.
700    1_
$a Iskander, K $u Amgen Inc., Thousand Oaks, CA, USA.
700    1_
$a Goldschmidt, H $u Universitatsklinikum Heidelberg, Heidelberg, Germany.
773    0_
$w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 31, č. 12 (2017), s. 2630-2641
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28439109 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180515103754 $b ABA008
999    __
$a ok $b bmc $g 1300270 $s 1013486
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 31 $c 12 $d 2630-2641 $e 20170425 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
LZP    __
$a Pubmed-20180515

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace